TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens ...
“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” said Rob ...
Please provide your email address to receive an email when new articles are posted on . Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, ...
Latest addition to Alcon’s intraocular lens (IOL) portfolio expands surgeons’ presbyopia-correcting IOL (PC-IOL) offerings Vivity X-WAVE technology delivers extended range of vision while maintaining ...
†Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof ® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. “As ophthalmic practices ...
Alcon is a global leader in IOLs and controls 40%-50% of the market, by our estimate. Its AcrySof IQ IOL, which was launched in 1994, has been implanted in more than 135 million eyes, making it the ...